In silico modeling to predict drug-induced phospholipidosis

Toxicology and Applied Pharmacology

Volumn 269, Issue 2, 2013, Pages 195-204

  Choi, Sydney S ^a   Kim, Jae S ^a   Valerio, Luis G ^a   Sadrieh, Nakissa ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug safety; In silico toxicology; Phospholipidosis

Indexed keywords

1,4 BIS(2 CHLOROBENZYLAMINOMETHYL)CYCLOHEXANE; ALPHA [4 (FLUOREN 9 YLIDENEMETHYL)PHENYL] 2 PIPERIDINEETHANOL; AMANTADINE; AMIKACIN; AMIODARONE; AMITRIPTYLINE; BILIRUBIN; CHLORCYCLIZINE; CHLOROQUINE; CHLORPROMAZINE; CITALOPRAM; CLINDAMYCIN; CLOMIPRAMINE; CYCLIZINE; DIBEKACIN; ERYTHROMYCIN; ETHYL LOFLAZEPATE; FENFLURAMINE; FLUOXETINE; GENTAMICIN; HALOPERIDOL; HYDROXYZINE; IMIPRAMINE; INDORAMIN; IPRINDOLE; MAPROTILINE; MECLOZINE; MEPACRINE; PERHEXILINE; PROPRANOLOL;

ALGORITHM; ARTICLE; COMPUTER MODEL; DATA BASE; DRUG INDUCED PHOSPHOLIPIDOSIS; HISTOPATHOLOGY; LIPIDOSIS; MACHINE LEARNING; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY;

ANIMALS; ARTIFICIAL INTELLIGENCE; COMPUTER SIMULATION; LIPIDOSES; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS;

EID: 84876725644     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.03.010     Document Type: Article

References (33)

1. ADMET Predictor User Manual 2011, Published by Simulations Plus, Lancaster, CA.
2. Baldi P., Brunak S., Chauvin Y., Andersen C.A.F., Nielsen H. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics 2000, 16:412-424.
3. Bandyopadhyay S., Klaunig J.E., Somani P. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology 1990, 12:48-58.
4. Cohen J. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 1960, 20:37-46.
5. Cooper J.A., Saracci R., Cole P. Describing the validity of carcinogen screening tests. Br. J. Cancer 1979, 39:87-89.
6. FDA The regulatory challenges of phospholipidosis. Advisory Committee Meeting. Silver, Spring, MD April 14, 2010 2010, (URL accessed August 6, 2012; http://www.fda.gov/AdvisoryCommittees/Calendar/ucm204093.htm).
7. Gum R.J., Hickman D., Fagerland J.A., Heindel M.A., Gagne G.D., Schmidt J.M., Michaelides M.R., Davidsen S.K., Ulrich R.G. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 2001, 62:1661-1673.
8. Hanumegowda U.M., Wenke G., et al. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem. Res. Toxicol. 2010, 23:749-755.
9. Hong H., Xie Q., Ge W., Qian F., Fang H., Shi L., Su Z., Perkins R., Tong W. Mold2, molecular descriptors from 2D structures for chemoinformatics and toxicoinformatics. J. Chem. Inf. Model. 2008, 48:1337-1344.
10. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 1984, 55:53-76.
11. Kodavanti U.P., Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 1990, 42:327-354.
12. Kruhlak N.L., Choi S.S., Contrera J.F., Weaver J.L., Willard J.M., Hastings K.L., Sancilio L.F. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol. Mech. Methods 2008, 18:217-227.
13. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
14. Lullmann H., Lullmann-Rauch R., Wassermann O. Drug-induced phospholipidosis. CRC Crit. Rev. Toxicol. 1975, 4:185-218.
15. Matthews B.W. Comparison of the predicted and observed secondary structure of T4 page lysozyme. Biochim. Biophys. Acta 1975, 405:442-451.
16. Mesens N., Steemans M., Hansen E., Peters A., Verheyen G., Vanparys P. A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. Toxicol. In Vitro 2009, 23:217-226.
17. Mesens N., Steemans M., Hansen E., Verheyen G.R., Van G.F., Van G.J. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol. In Vitro 2010, 24:1417-1425.
18. Morelli J.K., Buehrle M., Pognan F., Barone L.R., Fieles W., Ciaccio P.J. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. 2006, 22:15-27.
19. Muehlbacher M., Tripal P., Roas F., Kornhuber J. Identification of drugs inducing phospholipidosis by novel in vitro data. ChemMedChem 2012, 7:1925-1934.
20. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol. Sci. 2007, 99:162-173.
21. Orogo A., Choi S., Minner B., Kruhlak N. Construction and consensus performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds. Mol. Inf. 2012, 31:725-739.
22. Pelletier D.J., Gehlhaar D., Tilloy-Ellul A., Johnson T.O., Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model. 2007, 47:1196-1205.
23. Ploemen J.P., Kelder J., Hafmans T., van de Sandt H., van Burgsteden J.A., Saleminki P.J., van E.E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol. 2004, 55:347-355.
24. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5:567-583.
25. Sawada H., Taniguchi K., Takami K. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005, 83:282-292.
26. Schmitz G., Grandl M. Endolysosomal phospholipidosis and cytosolic lipid droplet storage and release in macrophages. Biochim. Biophys. Acta 2009, 6(SI):524-539.
27. Svetnik V., Liaw A., Tong C., Culberson C., Sheridan R.P., Feuston B.P. Random forest: a classification and regression tool for compound classification and QSAR modeling. J. Chem. Inf. Comput. Sci. 2003, 43:1947-1958.
28. Thompson K.L., Zhang J., Stewart S., Rosenzweig B.A., Shea K., Mans D., Colatsky T. Comparison of urinary and serum levels of di-22:6 bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. Toxicol. Lett. 2012, 213:285-291.
29. Tomizawa K., Sugano K., Yamada H., Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 2006, 31:315-324.
30. Valerio L.G. In silico toxicology for the pharmaceutical sciences. Toxicol. Appl. Pharmacol. 2009, 241:356-370.
31. Valerio L.G., Prous J., Valencia A., Mensa X. Computational modeling for QT prolongation: a drug cardiovascular endpoint of paramount importance. The Toxicologist 2011, 126. Oxford Journals, Washington, D.C. Society of Toxicology (Ed.).
32. Valerio L.G., Dixit A., Moghaddam S., Mora O., Prous J., Valencia A. QSAR modeling for the mutagenic potential of drug impurities with symmetry®. The Toxicologist 2012, Oxford Journals, San Francisco, CA, (Supp.).
33. Vitovic Pavol, Alakoskela Juha-Matti, Kinnunen Paavo K.J. Assessment of drug-lipid complex formation by a high-throughput langmuir-balance and correlation to phospholipidosis. J. Med. Chem. 2008, 51:1842-1848.